 LV dysfunction  Vasospasm and ischemia  Hypertension  VTE  Conduction disease  Arrhythmias.

Slides:



Advertisements
Similar presentations
1 Title 1 Subtitle 2 Chemotherapy Induced Cardiac Toxicity Russell Huntsinger, MD Cardiologist.
Advertisements

1Kitasato-Harvard Symposium 10/03/2002 New Monoclonal Antibody Approved for Advanced Breast Cancer Shin-ichi Nihira, Ph.D. Dept. Clinical Research 3 Chugai.
Integration of Taxanes in the Management of Breast Cancer
CARDIOVASCULAR EFFECTS OF ANTHRACYCLINE-LIKE CHEMOTHERAPY AGENTS JOHN N. HAMATY FACC, FACOI.
Therapy-Related Cardiac Toxicity in Cancer Patients JEAN-BERNARD DURAND, M.D., FCCP, FACC ASSOCIATE PROFESSOR OF MEDICINE MEDICAL DIRECTOR CARDIOMYOPATHY.
Perioperative Management of Heart Failure Gamal Fouad S Zaki, MD Professor of Anesthesiology Ain Shams University
Gefitinib EGFR inhibitor Non-small cell lung cancer Rash & diarrhea.
CARDIAC TOXICITY Prof. Maria PENCO Cardiologia UNIVERSITÀ DEGLI STUDI DELL’AQUILA SUPPORTIVE CARE IN ONCOLOGY Rome April 8, 2011.
CARDIAC TOXICITY OF CANCER THERAPEUTIC AGENTS Dr Binjo J Vazhappilly Senior Resident.
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Memorial Sloan-Kettering Cancer Center
Anticancer Therapy: Kinase Inhibitors Charles Harrell.
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Monoclonal antibodies in solid tumors.
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)
Drug Treatment of Metastatic Breast Cancer
HER2-Targeted Therapy THE PROBLEM WITH ‘OFF TARGET’ TOXICITY TO THE HEART Melinda Telli, MD Instructor in Medicine Stanford University 9/12/2008.
IN THE NAME OF GOD By: Dr malek. References Am J Clin Pathol. 2008;130(5): © 2008 American Society for Clinical Pathology Bryant J, Picot J,
Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Acute STEMI: current approach
Targeted Therapies - little & large explained Chris Clarke Macmillan Lead Pharmacist LNR Cancer Network.
By MD., FAC.C Zagazig University. 1.Improve endothelial function 2.Stimulate angiogenesis 3.Mobilize bone-marrow derived stem cells 4.Reduce systemic.
Should clinicians routinely recommend trastuzumab (Herceptin) as part of the adjuvant therapy for all patients with Her2 positive early breast cancer?
Trials of Adjuvant Trastuzumab in HER2+ Early-Stage Breast Cancer Trial Study Regimen No. of Patients Disease-Free Survival (%) Hazard Ratio P-Value Overall.
Highlights in the Management of Breast Cancer Rome, May 25-26, 2007 CLINICAL CASE Dott.ssa Simona Gildetti Cattedra di Oncologia Medica Università “G.
Herceptin ® : leading the way in metastatic breast cancer care Steffen Kahlert.
Assistant Professor of Medicine Dana-Farber Cancer Institute
Abstract Introduction  What is a Herceptin (Trastuzumab) ?  Herceptin (Trastuzumab) is an monoclonal antibody,it is an example of targeted therapy an.
Ethnic Differences in the Prognostic Value of Coronary Artery Calcification for All-Cause Mortality Khurram Nasir MD MPH, Leslee J. Shaw PhD, Sandy T.
Anthracycline induced Cardiomyopathy AM Report December AM Report December
Heart failure: The national burden AHA. Heart disease and stroke statistics–2005 update. Koelling TM et al. Am Heart J. 2004;147:74-8. VBWG Affects 1 million.
Tyrosine Kinase Inhibitors PHL 425 Dr. Mohamed M. Sayed-AShmed.
Modern cardiology support for the acute oncology patient Chris Plummer Cardiology, Freeman Hospital.
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
Adjuvant systemic therapy in breast cancer Targeted therapies Update R. Paridaens Belgian Breast Meeting
Cancer Chemotherapy Dr.Azarm.  The goal of cancer treatment is eradication of cancer  If not possible shifts to palliation,amelioration and preservation.
Καρδιακή βλάβη από τη θεραπεία του καρκίνου Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ.
PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.
Five Year Update of Cardiac Dysfunction in NSABP B-31 A Randomized Trial of AC  Paclitaxel vs. AC  Paclitaxel with Trastuzumab.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Overview of the 2011 Food and Drug Administration.
Empowering induction therapy for locally advanced head and neck cancer A. Argiris1* & M. V. Karamouzis2 1Division of Hematology–Oncology, Department of.
Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.
Dottor Liberato Di Lullo Direttore U.O.C. DI ONCOLOGIA P.O. “F. Veneziale” Isernia e P.O. “A. Cardarelli” CB Chieti, 11 Dicembre 2012 La doxorubicina liposomiale.
Cardiotoxicity associated with the cancer therapeutic agent sunitinib Telli ML, Witteles RM, Fisher GA, Srinivas S. Reviewed by:
Pediatric GIST: KIT inhibitors & IGF1R-directed antibodies January 22, 2009 Katherine Janeway, MD.
Malignancy related cardiotoxicity. Cytotoxic drugs  Formation of free oxygen radicals  Induction of immunogenic reactions  Influence of the cytotoxic.
Michel G. Khouri Igor Klem Chetan Shenoy Jeffrey Sulpher Susan F. Dent
S. Spoelstra, PhD, RN Oncology Nursing Society
Bonnie Ky, MD, MSCE Assistant Professor of Medicine and Epidemiology
Volume 34, Pages (August 2017) Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the.
Chapter 4: Management of Chemotherapy-Associated Cardiomyopathy
Tyrosine Kinase Inhibitors PHL 425
A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer.
ASCO 2002 Advances in the Adjuvant Chemotherapy of Breast Cancer
Tyrosine Kinase Inhibitors PHL 417
Cardio-toxicity of anti-cancer therapy
Caris Molecular Intelligence®
Cardiac Toxicity on NSABP B-31
Maya Guglin, MD, PhD University of Kentucky, Lexington, KY
Best Practices in Cardio-Oncology
Joerg Herrmann, MD, Amir Lerman, MD, Nicole P
Krop I et al. SABCS 2009;Abstract 5090.
Jones SE et al. SABCS 2009;Abstract 5082.
Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.
Section III: Neurohormonal strategies in heart failure
Nat. Rev. Clin. Oncol. doi: /nrclinonc
BY: DR M.H Mansouri Cardiologist
Branford S et al. Proc ASH 2013;Abstract 254.
β-Blocker Use for the Stages of Heart Failure
Maintenance therapies in Multiple Myeloma
Presentation transcript:

 LV dysfunction  Vasospasm and ischemia  Hypertension  VTE  Conduction disease  Arrhythmias

 Anthracyclines  Doxorubicin (Adriamycin)  Epirubicin (Ellence)  Idarubicin (Idamycin PFS)  Alkylating agents  Cyclophosphamide (Cytoxan)  Ifosfamide (Ifex)  Antimetabolites  Clofarabine (Clolar)  Antimicrotubule agents  Docetaxel (Taxotere) Monoclonal antibody-based tyrosine kinase inhibitors Bevacizumab (Avastin) Trastuzumab (Herceptin) Proteasome inhibitor Bortezomib (Velcade) Small molecule tyrosine kinase inhibitors Dasatinib (Sprycel) Imatinib mesylate (Gleevec) Lapatinib (Tykerb) Sunitinib (Sutent) Yeh et al, Circulation 2004

 Antimetabolites ◦ Capecitabine (Xeloda) ◦ Flurouracil (Adrucil)  Mab based-TKI ◦ Bevacizumab (Avastin)  Small molecule TKI ◦ Erlotinib (Tarceva) ◦ Sorafenib (Nexavar)  Antimicrotubule agents ◦ Paclitaxel (Taxol) ◦ Docetaxel (Taxotere)

 Mab based-TKI ◦ Bevacizumab (Avastin)  Small molecule TKI ◦ Sorafenib (Nexavar) ◦ Sunitinib (Sutent)

 Alkylating agents ◦ Cisplatin  Angiogenesis inhibitors ◦ Lenalidomide (Revlimid) ◦ Thalidomide (Thalomid)  Small molecule TKI ◦ Erlotinib (Tarceva)  Histone deacetylase inhibitor ◦ Vorinostat (Zolinza)

 Angiogenesis inhibitors ◦ Thalidomide (Thalomid)  Antimicrotubule agents ◦ Paclitaxel (Taxol)

 Histone deacetylase inhibitor ◦ Vorinostat (Zolinza)  Misc ◦ Arsenic trioxide Small molecule tyrosine kinase inhibitors Dasatinib (Sprycel) Lapatinib (Tykerb) Nilotinib (Tasigna)

Type 1Type II DoxorubicinTrastuzumab Cellular destructionCellular dysfunction Cumulative /Dose dependentNon-cumulative /Non dose dependent Usually irreversibleUsually reversible. Ewer 2008

 Incidence of Doxorubicin-induced HF is  3% to 5% with 400 mg/m2,  7% to 26% at 550 mg/m2,  18% to 48% at 700 mg/m2  Maximum lifetime cumulative dose for doxorubicin is 400 to 550 mg/m2. Epirubicin or Idarubicin appear to have less incidence of HF

 Cumulative dose;  intravenous bolus administration;  higher single doses;  history of prior irradiation;  the use of other concomitant cardiotoxic agents  female gender;  Underlying cardiovascular disease; age (young and old age  increased length of time since anthracycline completion

Anthracycline Cardiotoxicity

Lemmens, K., K. Doggen, and G.W. De Keulenaer, Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation, (8): p

Guarneri, V., et al., Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol, (25): p Enlarged and edematous vacuole Pleomorphic mitochondrion Z band widening and splitting

 Wide variation in definition of cardiotoxicity.  Wide range of incidence of asymptomatic LV dysfunction (3.2% - 33%)

Copyright ©2010 American College of Cardiology Foundation. Restrictions may apply. Cardinale, D. et al. J Am Coll Cardiol 2010;55: Percentage of Responders According to the Time Elapsed From AC Administration and Start of HF Therapy

(depends on who you ask)

Stages in the evolution of HF and recommended therapy by stage. et al. Circulation 2001;104: Copyright © American Heart Association

Circulation 2003, 108:

 Normal LVEF >50% at baseline ◦ Baseline MUGA within first 100 mg/m2 in all patients. ◦ Next MUGA mg/m2. ◦ Next MUGA 450 mg /m2 ◦ (400 mg/m2 if high risk- Cyclophosphamide, CAD, abnormal ECG, mediastinal radiation) ◦ MUGA prior to every dose >450 mg/m2 ◦ DISCONTINUE IF  EF reduces ≥ 10% from baseline AND reaches ≤ 50% Schwartz RD et al, Amer J. Med. 82; , 1987

 Abnormal LVEF <50% at baseline ◦ Baseline MUGA within first 100 mg/m2 in all patients. ◦ Serial MUGAs prior to each subsequent dose. ◦ DISCONTINUE if LVEF ≥10% from baseline or absolute LVEF ≤ 30%

 Assessment of EF at 0, 3, 6, 9, 12 months  MUGA or Echo with Tissue Doppler assessment  Use the same modality in follow up  If >10% absolute LVEF reduction but >50% EF, please follow up with yearly echos.  If >10% reduction to <50%, please institute heart failure therapy and refer to a Cardiologist.  If hypertension or DM coexist, please consider ACEI as first line.

 LVEF = (ED counts – Background counts)- (ES counts – Background Counts) (ED counts – Background counts)

 Digoxin  Heparin  Hydralazine  Penicillin  Quinidine  Prazosin  Methyldopa  Quinidine

 Inclusion of LA in ES ROI  Inclusion of ascending aorta in ROI  Background too dark (falsely low counts)  Anterior wall motion abnormality.  Temporal smoothing of LV volume curve.

 Exclusion of LV apex in ES ROI  Background counts too high.  Inferoposterior wall motion abnormality.

ProsCons EasyInaccurate in many situations (Arrhythmias, drugs, inaccurate ROIs) “Highly reproducible”Radiation exposure. “Low interobserver and intraobserver variability. “ Costly – Medicare $291.3 SPECT MUGA $759 Standardized against contrast ventriculography EF. Low temporal and spatial resolution.

No change in EF, but indices of early diastolic function, showed a significant decrease. 1/3 peak filling rate/ the end-diastolic count (EDC) (1/3 PFR/EDC) 1/3 filling fraction (1/3 FF). Delayed time to peak filling – (Normal is less than 180 ms) Angiology 1999, Jan;50(1): Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography. Suzuki J, et al

Salerno M. Multi-modality imaging of diastolic function. J Nucl Cardiol. 2010;17:316–27 Count time curves from a patient prior to (A) and after (B) anthracycline treatment, with marked reduction in the slope of the curve (TPFR) representing abnormal diastolic filling

Ho C Y, Solomon S D Circulation 2006;113:e396-e398 Copyright © American Heart Association

 42 Women, mean age 47± 9 years  25 % women developed Trastuzumab mediated cardiac toxicity at 3 months.  TDI parameters: (S′), early diastolic (e′), and late diastolic (a′) velocities.  Doppler-independent strain

 Significant difference in the lateral S′ between normals and pts with LV dysfn.  Both peak global longitudinal and radial strain decreased as early as 3 months in the CM group  Biomarkers did not predict injury  MUGA EF was decreased in all 10 at 6 month follow up.

  >28 open studies looking at monitoring of cardiotoxicity.  11 looking at CMRI with 4 actively recruiting.